Skip to Content
Merck
  • Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation.

Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation.

Gut (2013-05-07)
Guido von Figura, John P Morris, Christopher V E Wright, Matthias Hebrok
ABSTRACT

Emerging evidence from mouse models suggests that mutant Kras can drive the development of pancreatic ductal adenocarcinoma (PDA) precursors from acinar cells by enforcing ductal de-differentiation at the expense of acinar identity. Recently, human genome-wide association studies have identified NR5A2, a key regulator of acinar function, as a susceptibility locus for human PDA. We investigated the role of Nr5a2 in exocrine maintenance, regeneration and Kras driven neoplasia. To investigate the function of Nr5a2 in the pancreas, we generated mice with conditional pancreatic Nr5a2 deletion (PdxCre(late); Nr5a2(c/c)). Using this model, we evaluated acinar differentiation, regeneration after caerulein pancreatitis and Kras driven pancreatic neoplasia in the setting of Nr5a2 deletion. We show that Nr5a2 is not required for the development of the pancreatic acinar lineage but is important for maintenance of acinar identity. Nr5a2 deletion leads to destabilisation of the mature acinar differentiation state, acinar to ductal metaplasia and loss of regenerative capacity following acute caerulein pancreatitis. Loss of Nr5a2 also dramatically accelerates the development of oncogenic Kras driven acinar to ductal metaplasia and PDA precursor lesions. Nr5a2 is a key regulator of acinar plasticity. It is required for maintenance of acinar identity and re-establishing acinar fate during regeneration. Nr5a2 also constrains pancreatic neoplasia driven by oncogenic Kras, providing functional evidence supporting a potential role as a susceptibility gene for human PDA.

MATERIALS
Product Number
Brand
Product Description

Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Tamoxifen citrate salt, ≥99%
Sigma-Aldrich
Caerulein, ≥95% (HPLC)
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Tamoxifen, analytical standard
Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
DAPI, for nucleic acid staining
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard